Cargando…
Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer
SIMPLE SUMMARY: Rectal cancer is the 8th most common cancer globally. Most patients with locally advanced rectal cancer receive neoadjuvant therapy based on 5-fluorouracil and radiotherapy showing variable responses. About 70–90% of patients present partial response, while 20% show treatment resista...
Autores principales: | Carvalho, Robson Francisco, do Canto, Luisa Matos, Cury, Sarah Santiloni, Frøstrup Hansen, Torben, Jensen, Lars Henrik, Rogatto, Silvia Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583090/ https://www.ncbi.nlm.nih.gov/pubmed/34771654 http://dx.doi.org/10.3390/cancers13215492 |
Ejemplares similares
-
Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
por: Jensen, Lars Henrik, et al.
Publicado: (2023) -
The repertoire of germline variants in patients with early‐onset rectal cancer
por: Beltrami, Caroline Moraes, et al.
Publicado: (2022) -
Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response
por: Canto, Luisa Matos do, et al.
Publicado: (2019) -
Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer
por: Carvalho, Robson Francisco, et al.
Publicado: (2022) -
The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)